Clinical and laboratory parallels of the efficiency of glutoxim in destructive pulmonary tuberculosis

The aim was to evaluate the efficacy of glutoxime in achieving haematostimulating, detoxifying and abacilliating effects in the treatment of tuberculosis based on clinical and laboratory data. Materials and methods. The study included 120 patients with newly detected destructive pulmonary tuberculosis aged 42.8±3.2 years (25-55 years); the main group consisted of 90 patients who received glutoxime 60 mg intramuscularly once a day for 10 days, then 60 mg every other day for 20 days with standard antituberculosis chemotherapy. The control group was formed of 30 first-diagnosed patients with pulmonary tuberculosis who received chemotherapy without glutoxime. We evaluated the dynamics of the calculated leucocytic index of intoxication according to Y.Y. Kalf-Kalif as an indicator of the level of endogenous intoxication after 30 days of treatment. Results. In a month from the beginning of treatment normalization of hematological parameters was noted in 86,7% of patients of the main group and 60% of the control group (p=0,002). Leukocytic index of intoxication in the patients of the main group receiving glutoxime decreased 6 times in comparison with the initial one. The achieved values were significantly lower compared to the control group (0.47±0.18 and 1.83±0.21, p≤0.05). The number of TB patients with sputum smear negativation in the main group after 1, 2 and 3 months of treatment was higher compared to the control group (differences were statistically insignificant). Conclusion. The use of Glutoxime in pathogenetic therapy of destructive tuberculosis provides a significant decrease in the laboratory index of endogenous intoxication.